The UK Government has secured access to five million doses of Moderna’s Covid-19 vaccine after interim data suggested that the shot is 94.5% effective.
The preliminary results come from an interim analysis of 95 cases in a phase III trial of the vaccine, of which 90 cases of Covid-19 were observed in the placebo group versus five cases in the vaccinated group.
Following the initial positive results, the UK Government announced that the vaccine could be delivered as early as Spring 2021, with the potential for more doses to be secured next year.
The vaccine, which Moderna produced in collaboration with the US Government's “Operation Warp Speed”, has been shown to last for up to 30 days in household fridges and at room temperature for up to 12 hours. It also remains stable at -20C, equal to most household or medical freezers, for up to six months.
This suggests it can be stored and transported much more easily than the Pfizer/BioNTech vaccine, which was announced the week before to be 90% effective at protecting people from coronavirus.
Meanwhile, a vaccine developed by the Gamaleya Center in Russia has been found to be 92% effective, the Russian Direct Investment Fund (RDIF) has said. The results come from a phase III trial of Sputnik V, which evaluated the vaccine’s efficacy among over 16,000 volunteers who received the shot or placebo 21 days after the first dose.
More info >
PharmaTimes website: UK strikes deal for five million doses of Moderna’s Covid-19 vaccine
PharmaTimes website: Russian says its “Sputnik V” Covid-19 vaccine is 92% effective
Pulse website: GPs to be paid £12.58 per jab as details set out for Covid vaccination campaign